EGFR and non-small cell lung carcinoma: Osimertinib, as the first third-generation EGFR-TKI for treating T790M resistance mutations, was recommended as the standard first-line treatment for advanced or metastatic NSCLC patients with EGFR mutations based on its remarkable efficacy and manageable safety (Fu et al., 2022).